Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics


Tenax Therapeutics, Inc. (TENX)

Today's Latest Price: $1.44 USD

0.06 (-4.00%)

Updated May 29 4:00pm

Add TENX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TENX Daily Price Range
TENX 52-Week Price Range

TENX Stock Price Chart More Charts


TENX Price/Volume Stats

Current price $1.44 52-week high $1.77
Prev. close $1.50 52-week low $0.25
Day low $1.40 Volume 462,254
Day high $1.57 Avg. volume 205,904
50-day MA $0.73 Dividend yield N/A
200-day MA $1.10 Market Cap 13.28M

Tenax Therapeutics, Inc. (TENX) Company Bio


Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.


TENX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

TENX Latest Social Stream


Loading social stream, please wait...

View Full TENX Social Stream

Latest TENX News From Around the Web

Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.

Hedge Funds Are Warming Up To Tenax Therapeutics Inc (TENX)

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | May 29, 2020

TENX: Full Year 2019 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) completed enrollment of its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) and announced that the last patient has completed their final visit as of April 9. This 37 patient open-label trial achieved an 84% initial response rate for screened patients, and is

Yahoo | April 13, 2020

Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces last visit completed in Phase 2 levosimendan trial in PH-HFpEF. Top-line data readout in Q2.

Business Wire | April 9, 2020

Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 "HELP Study" of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Tenax Therapeutics, Inc. (NASDAQ: TENX) announces last visit completed in Phase 2 levosimendan trial in PH-HFpEF. Top-line data readout in Q2.

Yahoo | April 9, 2020

Companies Like Tenax Therapeutics (NASDAQ:TENX) Can Be Considered Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | March 19, 2020

Read More 'TENX' Stories Here

TENX Price Returns

1-mo 129.34%
3-mo 25.12%
6-mo 15.20%
1-year 9.09%
3-year -86.15%
5-year -98.07%
YTD 2.13%
2019 16.53%
2018 -87.65%
2017 -74.87%
2016 -40.55%
2015 -14.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.738 seconds.